# Mega Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mega-genomics

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.megagenomics.cn
- Total disclosed funding: $25M
- Latest round: Series A (Oct 27, 2016)
- Investors on record: 4

## About

Mega Genomics is a genomic testing company based in Beijing, specializing in advanced genetic analyses to assess disease risks and provide personalized health insights.Founded in 2016 in Beijing, China, Mega Genomics focuses on genomic testing services. The company has not undergone any notable pivots in its business strategy. Zhe Xiao leads the company as CEO. In June 2022, Mega Genomics completed an IPO, raising HKD 215.28 million, which represents the total amount raised to date.Mega Genomics specializes in genomic testing services, offering comprehensive analyses of over 700,000 genetic loci and sequencing of more than 180,000 key exonic regions in the human genome. These services assess the risk of various diseases, including hereditary cancers, recessive genetic disorders, and complex diseases. The core product offerings encompass whole-genome testing and whole-exome sequencing packages designed for both adults and children, providing insights into drug efficacy, dietary recommendations, and fitness guidance tailored to individual genetic profiles. The company serves a diverse clientele, including healthcare providers, researchers, and individuals seeking personal health insights, primarily operating in the Chinese market with a focus on urban areas.The revenue model for Mega Genomics is structured around direct-to-consumer sales of its genomic testing services, which includes flagship offerings like the adult and pediatric whole-exome sequencing packages. Clients typically engage in transactions through a straightforward purchasing process on the company’s platform, where they can select from various testing options. Pricing structures may vary based on the service selected, with each testing package providing detailed assessments of genetic risks and personalized health recommendations. The company fosters partnerships with healthcare providers and research institutions, enabling broader access to its services while enhancing revenue potential through collaborative initiatives. Each transaction is processed as a one-time payment for the specific genomic service chosen by the client.Moving forward, Mega Genomics plans to introduce new products, although specific details and release dates are not outlined. The company is targeting expansion into additional markets with a focus on urban regions in China by 2024. The funds raised through the IPO in June 2022 will be utilized to support these growth initiatives, enhancing research capabilities and operational infrastructure to meet increasing demand.

## Funding rounds

- Series A, Oct 27, 2016, $25M — Shannan Haosheng Investment Management, E Fund Overseas Investment, Eastwest Capital, Maccura Biotechnology Co.Ltd

## Investors

- Shannan Haosheng Investment Management (https://capitalatlas.ai/funds/shannan-haosheng-investment-management) — Series A
- E Fund Overseas Investment (https://capitalatlas.ai/funds/e-fund-overseas-investment) — Series A
- Eastwest Capital — Series A
- Maccura Biotechnology Co.Ltd — Series A